ClinicalTrials.gg
RecruitingNCT07592585Updated Jul 7, 2026

Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis

A Phase 3 interventional study of VC005 and VC005 Placebo in Atopic Dermatitis, sponsored by Jiangsu vcare pharmaceutical technology co., LTD. Recruiting at 1 site in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Jiangsu vcare pharmaceutical technology co., LTD · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Planned enrollment
46th of 190
360 · median 164
Started
2026
with 31 others
Phase 3
60 of 206
21 open now
Primary completion
2028-05
later than 70 of 81 live
Registered
191st of 206
by date
Lead sponsor
9 of 206
Jiangsu vcare pharmaceutical technology co., LTD

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 46th largest by planned enrollment of the 190 interventional ones that give a count, is one of 32 that started in 2026, is one of 60 in phase 3, reaches primary completion later than 70 of the 81 other live ones, and was the 191st registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

58 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

A multicenter, randomized, double-blind, vehicle controlled phase III clinical study to evaluate the efficacy and safety of VC005 in adults and adolescents with mild to moderate atopic dermatitis

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects fully understand this study, are able to follow the relevant procedures of the trial, voluntarily participate in the clinical trial, and sign the form (ICF);
  2. The age requirement for signing the ICF is 12 years old or above, with no gender restrictions;
  3. During screening, the diagnosis of atopic dermatitis should be met according to the Hanifin-Rajka criteria.

Exclusion criteria

Exclusion Criteria:

  1. Patients whose AD course is judged by the investigator as unstable(spontaneous improvement or rapid worsening) within 2 weeks prior to baseline;
  2. At screening and baseline, lesions are localized only to the hands or feet, with no prior history of involvement of other typical areas (such as the face or flexural areas);
  3. Skin damage or abnormalities that may affect the evaluation of the drug administration site (e.g., pigmentation, extensive scarring, tattoos, etc., at the affected area);
  4. At screening and baseline, presence of skin diseases that may affect the evaluation of the administration site, including but not limited to: psoriasis, acne, skin cancer, generalized erythroderma, Netherton syndrome, etc.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    VC005 groups

    Drug: VC005

  • Placebo comparator
    VC005 Placebo group

    Drug: VC005 Placebo

Interventions

  • DrugVC005

    VC005 Placebo group with Local topical application

  • DrugVC005 Placebo

    VC005 Placebo group with Local topical application

06

What researchers measure

Primary outcomes

  1. Proportion of subjects achieving an Investigator's Global Assessment (IGA) response (defined as an IGA score of 0 or 1 with a reduction of ≥2 points from baseline)

    Time frame: Week 8

07

Study locations

1 of 1 sites recruiting
  • Chinese Academy of Medical Sciences Hospital for Skin Disease
    Nanjing, Jiangsu, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2028, 24 months after the start.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's planned 24 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
May 18, 2026
StartActual
May 12, 2026
Primary completionEst.
May 30, 2028
CompletionEst.
May 30, 2028
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07592585
Responsible party
Sponsor
First posted
May 18, 2026
Start date
May 12, 2026
Primary completion
May 30, 2028 (estimated)
Completion
May 30, 2028 (estimated)
Last update
Jul 7, 2026

Study contacts

xiaojuan lai
Contact
lai_xiaojuan@vcarepharmatech.com
+8615358160458
qianjin Lu
principal investigator · Chinese Academy of Medical Sciences Hospital for Skin Disease

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VC005

Start the discussion